Compare ELTX & ELMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | ELMD |
|---|---|---|
| Founded | 2011 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 208.1M |
| IPO Year | 2014 | 2010 |
| Metric | ELTX | ELMD |
|---|---|---|
| Price | $3.60 | $43.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $18.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 4.0M | 72.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.29 | ★ 46.55 |
| EPS | N/A | ★ 0.91 |
| Revenue | $2,301,000.00 | ★ $54,716,000.00 |
| Revenue This Year | N/A | $15.59 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | ★ N/A | $50.22 |
| Revenue Growth | N/A | ★ 13.83 |
| 52 Week Low | $2.66 | $17.73 |
| 52 Week High | $16.00 | $47.40 |
| Indicator | ELTX | ELMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 65.54 |
| Support Level | $2.66 | $23.51 |
| Resistance Level | $9.44 | N/A |
| Average True Range (ATR) | 0.82 | 1.84 |
| MACD | -0.05 | 0.33 |
| Stochastic Oscillator | 20.93 | 67.73 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.